Chronic Skin Conditions

Sanofi’s Amlitelimab Meets Phase 3 Goals in Eczema as Shares Fall on Tepid Efficacy

Analysts now view the OX40L antibody as a convenience-focused option with quarterly dosing rather than a direct rival to IL‑13/4 leaders.